2 minute read

MBHB Partner Kevin Noonan Quoted in Bloomberg BNA Article Entitled, "FDA Approves Amgen's Humira Biosimilar, Release Not Until 2017"

Kevin E. Noonan, Ph.D.September 27, 2016

McDonnell Boehnen Hulbert & Berghoff LLP partner Dr. Kevin Noonan is quoted in a September 27, 2016 edition of Bloomberg Life Sciences Law & Industry Report in an article entitled, “FDA Approves Amgen’s Humira Biosimilar, Release Not Until 2017.” Amgen Inc. won the FDA’s approval Sept. 23 for its Amjevita as a biosimilar of AbbVie’s blockbuster rheumatoid arthritis drug Humira (adalimumab), but its release could be delayed. View the article